Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Paraneoplastic Ma antigen family member 6A (PNMA6A) is a poorly characterized protein in humans, encoded on the X chromosome, and belongs to the PNMA (paraneoplastic antigen Ma) family of proteins. It is identified primarily by sequence homology to other paraneoplastic Ma antigens but does not have a well-defined molecular function or clear role in known biological pathways. PNMA6A is not currently considered a therapeutic target and is not known to interact with drugs. Disease associations are limited and include rare links to congenital hypothyroidism and Leber congenital amaurosis, but there is no evidence for a prominent role in cancer or other major disease categories.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Paraneoplastic Ma antigen family member 6A (PNMA6A).